2023 - Research.com Biology and Biochemistry in Belgium Leader Award
Erik De Clercq focuses on Virology, Chemical synthesis, Stereochemistry, Immunology and Virus. The Virology study combines topics in areas such as Reverse transcriptase, Reverse-transcriptase inhibitor and Efavirenz. His studies deal with areas such as Bicyclic molecule, Structure–activity relationship, Cytotoxicity and Biological activity as well as Chemical synthesis.
Erik De Clercq has researched Stereochemistry in several fields, including Amantadine, Zinc, Trypanosoma brucei, Cytotoxic T cell and Aryl. As a member of one scientific family, Erik De Clercq mostly works in the field of Immunology, focusing on Drug and, on occasion, Intensive care medicine, Hepatitis C and Hepacivirus. His Virus study combines topics in areas such as RNA-dependent RNA polymerase, Cowpox virus, Variola virus, Microbiology and Molecular biology.
His primary areas of study are Stereochemistry, Virology, Virus, Nucleoside and In vitro. His work deals with themes such as Nucleic acid, Ring, Biological activity, Structure–activity relationship and Chemical synthesis, which intersect with Stereochemistry. In his work, Enzyme and Efavirenz is strongly intertwined with Reverse transcriptase, which is a subfield of Virology.
Mutation and DNA is closely connected to Molecular biology in his research, which is encompassed under the umbrella topic of Virus. His studies in Nucleoside integrate themes in fields like Bicyclic molecule, Thymine, Uridine and Pyrimidine. His study in In vitro is interdisciplinary in nature, drawing from both Cell culture and In vivo.
Erik De Clercq mainly focuses on Stereochemistry, Virology, Pharmacology, Virus and Nucleoside. His Stereochemistry research includes themes of Cell culture, IC50, Cytotoxicity, Cytotoxic T cell and Chemical synthesis. His biological study spans a wide range of topics, including Rilpivirine and Reverse transcriptase, Reverse-transcriptase inhibitor.
His Pharmacology research incorporates elements of Integrase, Polymer and Anti hiv activity. His Virus research includes elements of Rubella, Potency, Amantadine and Smallpox. He interconnects Nucleic acid, Pyrimidine, Pyran, Organic chemistry and Viral replication in the investigation of issues within Nucleoside.
His scientific interests lie mostly in Stereochemistry, Virology, Virus, Reverse transcriptase and Nucleoside. His Stereochemistry study integrates concerns from other disciplines, such as Potency, Cell culture, Chemical synthesis and Strain. His Virology study incorporates themes from Rilpivirine and Computational biology.
His studies in Antiviral drug and Cidofovir are all subfields of Virus research. His Reverse transcriptase research incorporates elements of Structural motif, Structure–activity relationship, Drug resistance and Drug discovery. Erik De Clercq has researched Nucleoside in several fields, including Biological activity and Pyrimidine.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Antiviral drugs in current clinical use.
Erik De Clercq.
Journal of Clinical Virology (2004)
CXCR4-activated astrocyte glutamate release via TNFalpha: amplification by microglia triggers neurotoxicity.
Paola Bezzi;Maria Domercq;Liliana Brambilla;Rossella Galli.
Nature Neuroscience (2001)
1,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxathiole 2",2"-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity.
Rosa Alvarez;Sonsoles Velázquez;Ana San-Félix;Stefano Aquaro.
Journal of Medicinal Chemistry (1994)
Acyclic nucleoside phosphonates: a key class of antiviral drugs
Erik De Clercq;Antonín Holý.
Nature Reviews Drug Discovery (2005)
Strategies in the design of antiviral drugs
Erik De Clercq.
Nature Reviews Drug Discovery (2002)
The bicyclam AMD3100 story
Erik De Clercq.
Nature Reviews Drug Discovery (2003)
The design of drugs for HIV and HCV
Erik De Clercq.
Nature Reviews Drug Discovery (2007)
Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection
Erik De Clercq.
Medicinal Research Reviews (2000)
Clinical Potential of the Acyclic Nucleoside Phosphonates Cidofovir, Adefovir, and Tenofovir in Treatment of DNA Virus and Retrovirus Infections
Erik De Clercq.
Clinical Microbiology Reviews (2003)
Antivirals and antiviral strategies
Erik De Clercq.
Nature Reviews Microbiology (2004)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
KU Leuven
KU Leuven
Rega Institute for Medical Research
Rega Institute for Medical Research
KU Leuven
Rega Institute for Medical Research
Shandong University
Shandong University
KU Leuven
Rega Institute for Medical Research
University of Maryland, College Park
Korea Advanced Institute of Science and Technology
Chinese Academy of Sciences
Brigham Young University
Simon Fraser University
Ghent University
Université Laval
UK Centre for Ecology & Hydrology
Colorado State University
University of Leicester
Stanford University
Utrecht University
China Earthquake Administration
University of Zurich
National Institute for Biological Standards and Control
John Jay College of Criminal Justice